A
Aperion Biologics
Clinical-stage medical device company developing a technique to make animal-tissues usable for human applications
About Aperion Biologics
Aperion Biologics, founded in San Antonio, Texas, in 1996, operated as a medical device company focused on creating alternatives to human-based grafts using animal-based tissue technology. The company's core business involved developing cartilage, soft tissue, and bone replacement products. Its primary technology was designed to prevent immunological rejection of animal tissue in human transplantation, offering solutions for patients with ligament issues.
The company's product pipeline included treatments based on this specialized technology aimed at addressing the need for viable tissue grafts. Aperion Biologics went through several funding stages, including grants and venture capital rounds, to finance its research and development efforts. Records show a Series C2 venture round in May 2011. However, the company's journey concluded, and it is now listed as out of business as of December 2017.
It is important to distinguish this San Antonio-based entity from the Vienna, Austria-based APEIRON Biologics AG. APEIRON Biologics AG is an entirely separate company founded in 2003 that specializes in immuno-oncology and was acquired by Ligand Pharmaceuticals in 2024. The two companies, despite the similar names, have distinct histories, founders, and operational focuses.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Oct 2015 | $20M | $80M | Undisclosed | — |
| SERIES D✓Equity / VC | Feb 2013 | $770K | $3.1M | Hasso Plattner Ventures | — |
Growth signals
Latest recorded traffic for Aperion Biologics is 290 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Aperion Biologics in the San Antonio ecosystem
The Aperion Biologics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later3 investors entered at this stage
Deutsche Bank- LFLurie Investment Fund
Hasso Plattner Ventures
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Aperion Biologics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Aperion Biologics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










